Two recent papers from CHOP cancer researchers have advanced the understanding of treatment-resistant pediatric central nervous system tumors.

CHOP researchers have shown that adenovirus proteins use a process called phase separation to coordinate production of viral progeny, which could have broad implications.

CHOP researchers found that a series of “liquid biopsies” could less invasively and more accurately identify tumor changes in patients with high-risk neuroblastoma.

Four CHOP researchers are part of a world-class research team that will receive $25 million to study solid tumors in children, funded by Cancer Grand Challenges.

More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.

CHOP researchers have shown that linking a tumor-killing prodrug to a macromolecular carrier of the Poloxamer family improves retention of the drug in treatment-resistant neuroblastoma tumors.

CHOP researchers have developed a novel cancer therapy that targets proteins inside cancer cells that are essential for tumor growth and survival but have been historically impossible to reach.

The award was presented to the St. Baldrick’s Foundation-Stand Up 2 Cancer Pediatric Cancer Dream Team, co-led by CHOP, at the annual AACR conference.

CHOP researchers will receive funds to discover a new drug that targets MYCN, a transcription factor involved in some pediatric cancers.

The CHOP physician-researcher’s investigation into cause of and treatment for neuroblastoma has been supported by Conquer Cancer grants.